Lenalidomide-induced cytopenias: Relationship to hematologic improvement in patients with myelodysplastic syndromes (MDS)

被引：2
|
作者：
Sekeres, Mikkael A. [1 ]
Maciejewski, Jwoslaw P. [1 ]
Giagounidis, Aristoteles [2 ]
Wride, Kenton [3 ]
Knight, Robert D. [3 ]
Raza, Azra [4 ]
List, Alan F. [5 ]
机构：
[1] Cleveland Clin Taussig Canc, Cleveland, OH USA
[2] St Johannes Hosp, Duisburg, Germany
[3] Celgene Corp, Summit, NJ USA
[4] Univ Massachusetts, Med Ctr, Worcester, MA 01003 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.821.821
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
821
引用
收藏
页码：252A / 252A
页数：1
相关论文
共 50 条
  • [21] DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
    Gerds, A. T.
    List, A. F.
    Giagounidis, A.
    Hellstrom-Lindberg, E.
    Li, J. Shiansong
    Swern, A. S.
    Sugrue, M. M.
    Fenaux, P.
    Sekeres, M. A.
    LEUKEMIA RESEARCH, 2015, 39 : S109 - S109
  • [22] Treatment Sequence of Lenalidomide (LEN) and Hypomethylating Agents (HMAs) and the Impact on Clinical Outcomes for Patients with Myelodysplastic Syndromes (MDS)
    Zeidan, Amer M.
    Klink, Andrew J.
    Feinberg, Bruce
    McGuire, Michael
    BLOOD, 2017, 130
  • [23] CYTOGENETIC STUDIES IN 69 PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    WEH, HJ
    CALAVREZOS, A
    SEEGER, D
    KUSE, R
    HOSSFELD, DK
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1987, 38 (02) : 166 - 172
  • [24] Serum cytokine levels in patients with myelodysplastic syndromes (MDS).
    Allampallam, K
    Shetty, V
    Mundle, S
    Dutt, D
    Reddy, PL
    Alvi, S
    Galili, N
    Saberwal, GS
    Anthwal, S
    Shaikh, MW
    York, A
    Gezer, S
    Venugopal, P
    Raza, A
    BLOOD, 2001, 98 (11) : 269B - 270B
  • [25] CHROMOSOMAL RESULTS IN 50 PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    LESSARD, M
    BRIZARD, A
    GUILHOT, F
    TANZER, J
    BLUT, 1988, 56 (06): : C9 - C9
  • [26] Family History Of Hematologic Malignancies and Disorders In a Population Based Study Of Myelodysplastic Syndromes (MDS)
    Smith, Angela R.
    Warlick, Erica D.
    Fonstad, Rachel K.
    Roesler, Michelle A.
    Poynter, Jenny N.
    Hirsch, Betsy
    Nguyen, Phuong L.
    Cioc, Adina
    Ross, Julie A.
    BLOOD, 2013, 122 (21)
  • [27] Combination of thalidomide and etanercept (Tumor necrosis factor receptor OR TNFR) effective in improving the cytopenias of some patients with myelodysplastic syndromes (MDS).
    Raza, A
    Lisak, LA
    Tahir, S
    Billmeier, JM
    Willmann, HS
    Alvi, MI
    Bellak, DJ
    Gezer, S
    Venugopal, P
    BLOOD, 2002, 100 (11) : 340B - 340B
  • [28] The use of GM-CSF +/- r-HuEPO for the treatment of cytopenias associated with myelodysplastic syndromes (MDS)
    Thompson, J
    Gilliland, G
    Prchal, J
    Bennett, J
    Larholt, K
    Nelson, R
    Rose, E
    Dugan, M
    BLOOD, 1995, 86 (10) : 1337 - 1337
  • [29] Cost-effectiveness of lenalidomide in treating patients with transfusion-dependent myelodysplastic syndromes (MDS) in the United States.
    Goss, T. F.
    Szende, A.
    Schaefer, C. P.
    Totten, P. J.
    Wang, M. Y.
    List, A. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 332S - 332S
  • [30] Cost-effectiveness of lenalidomide in the treatment of patients with transfusion-dependent myelodysplastic syndromes (MDS) in the United States.
    Goss, TF
    Szende, A
    Brueckner, J
    Wang, M
    Schaefer, C
    List, AF
    BLOOD, 2005, 106 (11) : 388A - 389A
12345